Scientific evidence classification · Phase 6A preserved + Phase 6B additions
PWWP Compounds
& Bioactivity
Explore experimentally studied preparations separately from deposited research ligands, buffers, ions and unresolved chemical evidence. Every role is source- and target-context specific.
Combined Phase 6A + Phase 6B denominators. These groups overlap; the 109 structurally source-tagged research ligands are unchanged. Deposited components and reagents are not automatically biochemical binders.
Phase 6B · source-reviewed additions (separate from the Phase 6A snapshot)
13 matching new observations · 12 preparations
Keep source-level IC50, Kd, and whole-protein DC50 separate; these records were not included in the original 80.
| Preparation | Target scope | Original assay | Primary source |
|---|---|---|---|
| UNC10088 | NSD2 PWWP1, exact domain | IC50 =248 ± 22 nM TR-FRET competitive displacement of biotinylated UNC7096 | 10.1038/s41467-026-72235-9 Figure 2h and Supplementary Figure 3D |
| UNC10088 | NSD2 PWWP1, exact domain | IC50 =101 ± 8 nM TR-FRET competitive displacement of biotinylated UNC7096 | 10.1038/s41467-026-72235-9 Figure 2h, Supplementary Figure 3D and Results |
| UNC10415667 | NSD2 protein, cellular only | DC50 =460 nM Cellular HiBiT protein-degradation dose response | 10.1038/s41467-026-72235-9 Figure 3e legend and Results |
| UNC12149 | NSD2 protein, cellular only | DC50 =120 nM Cellular HiBiT protein-degradation dose response | 10.1038/s41467-026-72235-9 Figure 4h legend and Results |
| SYC2 | NSD3 PWWP, domain instance unresolved | Kd =0.07 ± 0.01 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher compound table row 28; SPR Kd (µM) column, corroborated by abstract |
| SYB7 | NSD3 PWWP, domain instance unresolved | Kd >20 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 20; SPR Kd (µM) column |
| SYB10 | NSD3 PWWP, domain instance unresolved | Kd =0.11 ± 0.07 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 23; SPR Kd (µM) column |
| SYB11 | NSD3 PWWP, domain instance unresolved | Kd =0.15 ± 0.03 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 24; SPR Kd (µM) column |
| SYC1 | NSD3 PWWP, domain instance unresolved | Kd =0.13 ± 0.04 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 27; SPR Kd (µM) column |
| SYC3 | NSD3 PWWP, domain instance unresolved | Kd =0.32 ± 0.11 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 29; SPR Kd (µM) column |
| SYC5 | NSD3 PWWP, domain instance unresolved | Kd =0.18 ± 0.03 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 31; SPR Kd (µM) column |
| SYC6 | NSD3 PWWP, domain instance unresolved | Kd =0.25 ± 0.06 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 32; SPR Kd (µM) column |
| SYC7 | NSD3 PWWP, domain instance unresolved | Kd =7.69 ± 0.32 µM SPR (publisher compound table header) | 10.1021/acs.jmedchem.6c00983 Publisher source compound table row 33; SPR Kd (µM) column |
Evidence classification · exact source records
26 matching profiles
72 matching assay / association observations. Counts here are profiles, not unique assay events or deposited ligand instances; views overlap.
UNC6934
BI-9466
No source-curated measured assay in this context. Structural evidence is shown separately.
BPP
Measurements remain attached to the reported preparation.
compound 1 (de Freitas 2021)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 11 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 12 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 13 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 5 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
compound 6 (Collie 2025)
Unresolved preparation · individual modeled components do not inherit its potency.
compound 7 (Collie 2025)
LLC0424
MR837 (3f)
MRT866
MS9715
Measurements remain attached to the reported preparation.
MS9715N
Unresolved preparation · individual modeled components do not inherit its potency.
UNC7096
UNC7145
No source-curated measured assay in this context. Structural evidence is shown separately.
Measurements remain attached to the reported preparation.
UNC7753
Unresolved preparation · individual modeled components do not inherit its potency.
UNC8153
Measurements remain attached to the reported preparation.
UNC8269
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
UNC8325
Unresolved preparation · individual modeled components do not inherit its potency.
Measurements remain attached to the reported preparation.
UNC8587
No source-curated measured assay in this context. Structural evidence is shown separately.
Unresolved preparation · individual modeled components do not inherit its potency.
UNC8732
Measurements remain attached to the reported preparation.
UNC8884
No source-curated measured assay in this context. Structural evidence is shown separately.
Unresolved preparation · individual modeled components do not inherit its potency.